Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.

Aiting YangXuzhen YanXu FanYiwen ShiTao HuangWeiyu LiWei ChenJidong JiaHong You

Published in: Hepatology international (2021)

LOXL1 may contribute to fibrosis progression in non-obese NAFLD, and HSCs-specific knockout of LOXL1 attenuated liver steatosis, inflammation, fibrosis, , and improved lipid metabolic abnormalities. Hence, LOXL1 inhibition may serve as a new therapeutic strategy for NASH.

Keyphrases

oxidative stress
adipose tissue
induced apoptosis
metabolic syndrome
weight loss
high fat diet induced
type diabetes
insulin resistance
fatty acid
high fat diet
liver fibrosis
cell cycle arrest
obese patients
signaling pathway
endoplasmic reticulum stress
cell death